Differential impact of immune-mediated inflammatory diseases before versus after cancer on patient survival: a nationwide cohort study
Our study highlights the differential impacts of IMIDs diagnosed before and after cancer onset on survival outcomes. While pre-existing IMIDs appear to exacerbate mortality risk, newly diagnosed IMIDs post-cancer may confer a survival advantage. Clinicians should consider the implications of IMIDs management in cancer patients to optimize treatment and improve overall survival.
Authors
- Guangtong Deng (ORCID: https://orcid.org/0000-0002-4424-9727)
- Ziyu Guo (ORCID: https://orcid.org/0000-0002-4792-1398)
- Furong Zeng (ORCID: https://orcid.org/0000-0001-6621-8131)
- Danyao Chen
- Minxue Shen (ORCID: https://orcid.org/0000-0003-0441-9303)
- Yuming Sun (ORCID: https://orcid.org/0009-0005-3823-5547)
- Jiayuan Le
Institutions
- Central South University (CN)
- SKiN Health (CA)
- Centre de Recherche en Sciences et Technologies de l'Information et de la Communication (FR)
- Hunan Cancer Hospital (CN)
- National Clinical Research (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1093/rheumatology/keaf213
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05